" Toxicology Project Leader"

OUR COMPANY– GENERAL OVERVIEW

Servier is an international pharmaceutical company governed by a non-profit Foundation and headquartered in France.

With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, we employ over 21,000 people worldwide.

Being completely independent, we reinvest 25% of turnover (excluding generics) in Research and Development and use all our profits in growth.

We are specialised and driven by our constant search for innovation in five major research areas: cardiovascular diseases, cancers, diabetes, immuno-inflammatory diseases and neurodegenerative diseases, as well as by our activities in high-quality generic drugs.

Currently, we have 23 drug candidates including 19 new molecular entities at various stages of clinical development.

Our priorities are pathologies with high medical needs within our areas of expertise.

Therapeutic Areas

Cancers

Becoming a key player in oncology is part of Servier's long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, targeted, immune and cellular therapies, to deliver life-changing medicines to patients.

Immune-inflammatory diseases

Becoming a key player in the fight against immune-inflammatory diseases is part of Servier's long-term strategy. Servier wishes to bring innovative therapeutic solutions to patients suffering from these pathologies, which are often highly debilitating. Its research focuses on lupus, Gougerot-Sjögren syndrome and scleroderma, for which there is no cure.

This goal will be reached by establishing partnerships worldwide, to contribute to the speeding up of marketing of innovative drugs with high added value for patients.

Neurodegenerative diseases

Servier has a solid commitment to neuropsychiatry and to proposing innovative therapies to patients suffering from neurological conditions. Its Research teams are investigating new ways to treat Alzheimer's and Parkinson's diseases, as well as a broad range of neurodegenerative disorders, by targeting the toxic proteins that lead to neuron death. The priority is on focusing on the causes of the diseases rather than their symptoms. Currently, there are 5 projects at different stages of research and development in this promising area. This portfolio of innovative treatments is being developed with academic and biotech partners worldwide.

Company Strategy & 2020 Goals

- Increase Research output : launch on the market one new molecular entity every 3 years

- Achieve sales of 5 billion Euros
- Become a key player in oncology and reinforce the group's presence in its historical therapeutic areas, especially cardiology.

THE JOB: **TOXICOLOGY PROJECT LEADER -** Localization: Gidy, Loiret(45) q(France)

We are seeking for a highly motivated project leader with a solid experience and knowledge in Toxicology to join a team of 6 project leaders in toxicology in charge of leading and evaluating the safety of ours internal and external drug candidates.

Reporting to the Toxicology Scientific Director , in the Non Clinical Safety Center of Excellence, you will join a team of 85 persons, mainly dedicated to early drug candidate selection and evaluation. It gathers a range of expertises on *in vivo* rodent and non rodent models and a panel of *in vitro* cellular models, with the support of local Study Directors and many laboratory teams (anatomo-pathology, pre-formulation and analytic or clinical biology).

Having a strong background in Toxicology, you will be empowered and responsible for the non clinical safety development strategy of the new chemical and biological candidates, from preclinical to MA Filing. Therefore, you will drive a project portfolio, working closely with all development actors and you will be proactive with regards to clinical development plans, regulation and each molecule's specificities.

The job is located in Gidy (Orléans – France) with some trips to Head Quarters in Suresnes (Paris Region).

Key duties and responsibilities

- Strategy assessment
- Supervision and coordination of development plans with cost/quality/delay performance
- Safety evaluation of our licensing in and out products (Due diligences)
- Scientific support for business actors in the implementation of safety studies and data analysis, in close interaction with different experts
- Project flowchart, risk and opportunities reporting
- Redaction of intern projects and regulation deliverables
- Projects overview communication to local actors
- Scientific and regulation monitoring on project environment
-
- **Skills and experience**
- Master or PhD degree in Pharmacy or Biology
- A minimum of 5 years' experience within the non-clinical development of chemical and biological molecules in a pharmaceutical industry
- Strong knowledge in non clinical development legislation and strategies
- Strong background in animal physiopathology, non clinical safety studies and regulatory files
- Empowerment
- Rigor, professionalism, proactive, reactive
- Organization and priorities oriented in a portfolio management context
- Excellent oral and written communication and interpersonal skills
- Appetence for internal and external partnership and collaboration
- Strong problem solving and analytical skills
- English level: scientific oral and writing.

If you recognize yourself in this description and you feel ready to take this challenge, send us yourapplication , ref.845, to: katia.da-cruz@servier.com